Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of avenciguat in progressive systemic sclerosis
CTR20222730Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of avenciguat in systemic sclerosis (SSc), sponsored by Boehringer Ingelheim. Started Apr 2023; status: completed.
02
Drugs
avenciguat
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on CTR20222730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222730.